EVIDENCE-BASED JOINT SUPPORT FOR DOGS

JOINT CARE FOR CANINE OSTEOARTHRITIS

Osteoarthritis (OA) is a progressive, inflammatory and degenerative joint disease affecting up to 20% of adult dogs and over 80% of senior dogs. Effective management requires a multimodal approach targeting inflammation, cartilage integrity and joint biomechanics.

BDS Animal Health mobility formulations are developed using clinically studied nutraceutical ingredients manufactured under GMP-aligned quality systems to ensure consistency, purity and bioavailability.

 

THE SCIENCE BEHIND BDS ANIMAL HEALTH JOINT FORMULATIONS

Our formulations combine three extensively researched ingredients:

GLUCOSAMINE HCl

  • Precursor for glycosaminoglycan (GAG) synthesis
  • Supports cartilage matrix integrity
  • Reduces cartilage catabolism
  • Contributes to improved joint mobility

Randomised clinical trials in dogs with naturally occurring OA have demonstrated statistically significant improvements in pain and mobility scores when glucosamine is administered alone or in combination therapy.

CHONDROITIN SULPHATE

  • Inhibits cartilage-degrading enzymes
  • Supports proteoglycan production
  • Maintains synovial fluid viscosity
  • Modulates synovial inflammation

Combination glucosamine–chondroitin therapy has shown measurable improvements in clinical lameness indices and peak vertical force in controlled veterinary studies.

GREEN-LIPPED MUSSEL (PERNA CANALICULUS)

  • Source of omega-3 fatty acids including ETA, EPA and DHA
  • Contains bioactive marine glycosaminoglycans
  • Demonstrates anti-inflammatory activity
  • Improves mobility and peak vertical force in dogs

Controlled studies show that Perna canaliculus supplementation improves mobility scores and reduces pain markers in dogs with OA.

 

WHY COMBINATION THERAPY MATTERS

Osteoarthritis is multifactorial. Structural degeneration, inflammatory mediators and altered biomechanics all contribute to disease progression.

Glucosamine and chondroitin support cartilage metabolism.

Green-lipped mussel provides anti-inflammatory lipid fractions and omega-3 fatty acids.

Together, they deliver structural and inflammatory pathway support — aligned with modern multimodal OA management principles.

 

QUALITY DIFFERENTIATION

Ingredient variability is one of the largest weaknesses in the nutraceutical industry.

BDS Animal Health ensures:

  • Defined active inclusion rates
  • Controlled raw material sourcing
  • Batch traceability
  • GMP-aligned manufacturing
  • Consistent dose delivery